MID-VOLUME · HOSP-HEAVY
valganciclovir Side Effects
valganciclovir (also sold as Valcyte) sits MID-VOLUME #247 of 524 by FAERS report count. Lead signal: HOSP-HEAVY - 49.1% mention hospitalization (8,858 reports). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 18,056
- FAERS reports
FDA Adverse Event Reporting System extract for valganciclovir. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-HEAVY. How figures are compiled.
valganciclovir: 49.1% mention hospitalization (8,858 reports). Death stamp DEATH-HEAVY; volume band MID-VOLUME #247 of 524 by FAERS report count.
Mid-book FAERS page for valganciclovir (Valcyte) (18,056 reports). Signature HOSP-HEAVY. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
CYTOMEGALOVIRUS INFECTION leads 1,756 of 18,056 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (5,201 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (3,133 reports, 17.4%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 754 |
| SEPSIS | 300 |
| CYTOMEGALOVIRUS INFECTION | 256 |
| PANCYTOPENIA | 255 |
| SEPTIC SHOCK | 234 |
| ACUTE KIDNEY INJURY | 227 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 214 |
| RESPIRATORY FAILURE | 213 |
| PNEUMONIA | 206 |
| NEUTROPENIA | 154 |
| THROMBOCYTOPENIA | 147 |
| LEUKOPENIA | 146 |
| PYREXIA | 146 |
| CYTOMEGALOVIRUS INFECTION REACTIVATION | 132 |
| DIARRHOEA | 128 |
| RENAL FAILURE | 119 |
| MYELOSUPPRESSION | 105 |
| CYTOMEGALOVIRUS VIRAEMIA | 100 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (8,858, 49.1% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| PYREXIA | 736 |
| CYTOMEGALOVIRUS INFECTION | 710 |
| DIARRHOEA | 658 |
| NEUTROPENIA | 585 |
| ACUTE KIDNEY INJURY | 531 |
| LEUKOPENIA | 514 |
| ANAEMIA | 461 |
| PANCYTOPENIA | 420 |
| PNEUMONIA | 409 |
| THROMBOCYTOPENIA | 382 |
| NAUSEA | 367 |
| VOMITING | 350 |
| TRANSPLANT REJECTION | 347 |
| SEPSIS | 339 |
| BLOOD CREATININE INCREASED | 318 |
| URINARY TRACT INFECTION | 300 |
| RENAL IMPAIRMENT | 299 |
| DRUG INTERACTION | 285 |
How to read valganciclovir FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-HEAVY)
FAERS holds 18,056 voluntary reports linked to valganciclovir (Valcyte), 2004-2025. Death is listed on 3,133 (17.4%). Hospitalization appears on 8,858 (49.1%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-HEAVY as signal-detection rates next to 49.1% mention hospitalization (8,858 reports).
Read with valganciclovir
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.
ABS(total_reports) peer at 17,976 FAERS cases (Δ 80 lighter vs valganciclovir); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 17,969 FAERS cases (Δ 87 lighter vs valganciclovir); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 18,159 FAERS cases (Δ 103 heavier vs valganciclovir); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 18,237 FAERS cases (Δ 181 heavier vs valganciclovir); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 44.8 pp vs valganciclovir's DEATH-HEAVY): CASELOAD · HOSP-MID.
valganciclovir stamps DEATH-HEAVY · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.